drugset / Trial / NCT01282632

Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression

NCT01282632

Phase 1/2 Completed 42 enrolled Sunnybrook Health Sciences Centre
RandomizedSingle-groupQuadruple-blindTreatment

Summary

Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative efficacy and tolerability in treatment resistant depression. The current study was designed as a pilot study to examine efficacy and tolerability of Olanzapine vs. Risperidone add on to a failed serotonin re-uptake inhibitor (SSRI) in depression.

Timeline

Start
2002-08
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 15 mg Oral
Subject Risperidone Other / unclassified 3 mg Oral